Thymic Carcinoma Clinical Trials

42 clinical trials for Thymic Carcinoma across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma — RECRUITING · PHASE2
• Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma — RECRUITING · PHASE1
• Neoadjuvant Treatment For Locally Advanced Thymic Cancer — RECRUITING · PHASE2
• Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) — RECRUITING · PHASE3
• A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors — RECRUITING · PHASE2
• Molecular Analysis of Thoracic Malignancies — RECRUITING
• Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma — RECRUITING · PHASE2
• CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors — RECRUITING · PHASE1
• Molecular Analysis and Treatment Options of Thymic Malignancies — RECRUITING
• Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors — RECRUITING
• A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors — NOT_YET_RECRUITING · NA
• IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) — ACTIVE_NOT_RECRUITING · PHASE2
• Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma — NOT_YET_RECRUITING · PHASE2
• Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis — NOT_YET_RECRUITING
• Survival Nomogram for Patients With Thymic Carcinoma — COMPLETED · NA
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors — COMPLETED · PHASE1
• Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) — OTHER · PHASE2
• A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors — TERMINATED · PHASE2
• KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma — TERMINATED · PHASE2
• Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma — COMPLETED · PHASE2
• Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S — COMPLETED · PHASE1
• A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors — COMPLETED · PHASE1
• Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy — COMPLETED · PHASE2
• Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) — OTHER · PHASE2
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas — TERMINATED · PHASE1
• Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma — OTHER · PHASE2
• Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy — TERMINATED · PHASE2
• Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma — COMPLETED · PHASE2
• A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies — COMPLETED · PHASE2
• Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma — TERMINATED · PHASE2
• A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma — COMPLETED · PHASE2
• A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies — TERMINATED · PHASE1
• Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer — OTHER
• Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy — COMPLETED · PHASE2
• Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage — COMPLETED · PHASE2
• Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma — COMPLETED · PHASE1
• Paclitaxel and Cisplatin for Thymic Neoplasm — TERMINATED · PHASE2
• Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases — COMPLETED · PHASE2

Refine this search